FCE 20696

Drug Profile

FCE 20696

Latest Information Update: 30 May 2001

Price : $50

At a glance

  • Originator Pharmacia Corporation
  • Class Benzopyrans; Small molecules
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Rheumatic disorders; Viral infections

Most Recent Events

  • 30 May 2001 Profile reviewed but no significant changes made
  • 31 Aug 1998 No-Development-Reported for Rheumatic disorders in Italy (PO)
  • 13 Mar 1995 No-Development-Reported for Viral infections in Italy (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top